CL2017000792A1 - Derivados del ácido borónico - Google Patents

Derivados del ácido borónico

Info

Publication number
CL2017000792A1
CL2017000792A1 CL2017000792A CL2017000792A CL2017000792A1 CL 2017000792 A1 CL2017000792 A1 CL 2017000792A1 CL 2017000792 A CL2017000792 A CL 2017000792A CL 2017000792 A CL2017000792 A CL 2017000792A CL 2017000792 A1 CL2017000792 A1 CL 2017000792A1
Authority
CL
Chile
Prior art keywords
acid derivatives
boronic acid
malignities
lmp
hematological
Prior art date
Application number
CL2017000792A
Other languages
English (en)
Inventor
Markus Klein
Oliver Schadt
Philipp Haselmayer
Mireille Krier
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2017000792A1 publication Critical patent/CL2017000792A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>LOS COMPUESTOS DE FORMULA (I) SON INHIBIDORES DE LMP/ Y PUEDEN EMPLEARSE, ENTRE OTROS, PARA EL TRATAMIENTO DE UN TRASTORNO AUTOINMUNE O MALIGNIDADES HEMATOLÓGICAS.</p>
CL2017000792A 2014-10-01 2017-03-31 Derivados del ácido borónico CL2017000792A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14003389 2014-10-01

Publications (1)

Publication Number Publication Date
CL2017000792A1 true CL2017000792A1 (es) 2017-11-10

Family

ID=51751859

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000792A CL2017000792A1 (es) 2014-10-01 2017-03-31 Derivados del ácido borónico

Country Status (21)

Country Link
US (1) US10669289B2 (es)
EP (1) EP3201206B1 (es)
JP (1) JP6662865B2 (es)
KR (1) KR102457840B1 (es)
CN (1) CN107001391B (es)
AU (1) AU2015327345B9 (es)
BR (1) BR112017006622A2 (es)
CA (1) CA2963203A1 (es)
CL (1) CL2017000792A1 (es)
DK (1) DK3201206T3 (es)
ES (1) ES2761774T3 (es)
IL (1) IL251302B (es)
MX (1) MX2017003999A (es)
MY (1) MY186911A (es)
NZ (1) NZ730981A (es)
PH (1) PH12017500293A1 (es)
RU (1) RU2717558C2 (es)
SG (1) SG11201702628XA (es)
UA (1) UA122672C2 (es)
WO (1) WO2016050358A1 (es)
ZA (1) ZA201703007B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053247B2 (en) 2014-10-01 2021-07-06 Bristol-Myers Squibb Company Pyrimidinones as factor XIA inhibitors

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015327346B2 (en) 2014-10-01 2019-12-05 Merck Patent Gmbh Boronic acid derivatives
MX2017004043A (es) 2014-10-01 2017-07-04 Merck Patent Gmbh Derivados de acido boronico.
CA2963186A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
KR102534947B1 (ko) * 2017-01-18 2023-05-23 프린시피아 바이오파마, 인코퍼레이티드 면역프로테아좀 억제제
KR20200040295A (ko) * 2017-08-24 2020-04-17 메르크 파텐트 게엠베하 보론산 유도체
CN111065619B (zh) * 2017-08-29 2022-08-12 浙江海正药业股份有限公司 (E)-α,β-不饱和酰胺化合物及其制备方法和用途
WO2019075386A1 (en) * 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
WO2019099576A1 (en) 2017-11-16 2019-05-23 Principia Biopharma Inc. Immunoproteasome inhibitors
NZ764393A (en) * 2017-11-16 2023-11-24 Principia Biopharma Inc Immunoproteasome inhibitors
BR112021001359A2 (pt) 2018-07-26 2021-04-20 Merck Patent Gmbh derivados de ácido borônico
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
IL310390A (en) 2021-07-29 2024-03-01 Merck Patent Gmbh Crystalline forms of [(R1)-2-benzofuran-3-yl)-1-{[(R4, R2, S1)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, Their adducts and their use
WO2023061445A1 (zh) * 2021-10-14 2023-04-20 首药控股(北京)股份有限公司 硼酸衍生物
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658885A (en) * 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
US5462964A (en) * 1993-10-20 1995-10-31 The Du Pont Merck Pharmaceutical Company Dipeptide boronic acid inhibitors of trypsin-like enzymes
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
AU5788800A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
JP2006509034A (ja) * 2002-09-09 2006-03-16 トライジェン・リミテッド 選択性トロンビン阻害のための非経口製剤に有用なボロン酸塩
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN1867572B (zh) * 2003-08-14 2012-03-28 赛福伦公司 蛋白酶体抑制剂及其使用方法
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
NZ603364A (en) 2010-04-22 2015-06-26 Mars Inc Inhibitors of arginase and their therapeutic applications
EP2793900B1 (en) * 2011-12-22 2018-08-22 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
JP6464176B2 (ja) 2014-01-31 2019-02-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
SG11201702463YA (en) 2014-10-01 2017-04-27 Janssen Pharmaceuticals Inc Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
NO2721243T3 (es) 2014-10-01 2018-10-20
MX2017004043A (es) 2014-10-01 2017-07-04 Merck Patent Gmbh Derivados de acido boronico.
CA2963186A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
AU2015327346B2 (en) 2014-10-01 2019-12-05 Merck Patent Gmbh Boronic acid derivatives
ME03344B (me) 2014-10-01 2019-10-20 Janssen Pharmaceuticals Inc Mono- ili di-supstituisani indoli kao inнibitori replikacije denga virusa

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053247B2 (en) 2014-10-01 2021-07-06 Bristol-Myers Squibb Company Pyrimidinones as factor XIA inhibitors

Also Published As

Publication number Publication date
RU2717558C2 (ru) 2020-03-24
KR20170067802A (ko) 2017-06-16
CN107001391B (zh) 2020-11-27
NZ730981A (en) 2024-01-26
UA122672C2 (uk) 2020-12-28
AU2015327345B9 (en) 2020-06-18
DK3201206T3 (da) 2019-12-16
JP6662865B2 (ja) 2020-03-11
RU2017115192A (ru) 2018-11-06
IL251302B (en) 2020-03-31
US10669289B2 (en) 2020-06-02
EP3201206B1 (en) 2019-09-18
PH12017500293A1 (en) 2017-06-28
EP3201206A1 (en) 2017-08-09
KR102457840B1 (ko) 2022-10-21
SG11201702628XA (en) 2017-04-27
AU2015327345A1 (en) 2017-05-18
CN107001391A (zh) 2017-08-01
JP2017531646A (ja) 2017-10-26
RU2017115192A3 (es) 2019-03-26
US20180179232A1 (en) 2018-06-28
AU2015327345B2 (en) 2019-12-05
ES2761774T3 (es) 2020-05-21
WO2016050358A1 (en) 2016-04-07
MY186911A (en) 2021-08-26
BR112017006622A2 (pt) 2018-07-03
IL251302A0 (en) 2017-05-29
MX2017003999A (es) 2018-02-09
ZA201703007B (en) 2022-05-25
CA2963203A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
CL2017000792A1 (es) Derivados del ácido borónico
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2017003404A1 (es) Compuestos antibacterianos
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
EA201691916A1 (ru) Биарильные ингибиторы киназы
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
AR095075A1 (es) Acoplamiento electroquímico de anilinas
MX2017004043A (es) Derivados de acido boronico.
MX2017004037A (es) Derivados de acido boronico.
MX370336B (es) Derivados de acido boronico.
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
CL2016001623A1 (es) Compuestos de benzamida y nicotinamida y métodos para usar los mismos.
CL2017000151A1 (es) Derivados de piridona
MX2017004655A (es) Compuestos de hidroxil purinas y aplicaciones de estos.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
BR112016027455A2 (pt) moduladores ppar
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза